Biofrontera Inc., a U.S. biopharmaceutical company specializing in dermatological treatments, will report its third quarter 2026 financial results on November 13 before the market opens. The company will hold a conference call and webcast at 10:00 a.m. Eastern Time the same day to discuss the results and provide a business update. Biofrontera focuses on photodynamic therapy products like Ameluz® and RhodoLED® Lamps, recently approved by the FDA for treating superficial basal cell carcinoma. This upcoming report will give investors insight into the company's financial health and progress following recent FDA approvals and product developments.
Biofrontera Inc.'s upcoming Q3 2026 financial report provides context for readers interested in health sector stocks. As of November 7, 2026, 77 out of 150 priced health-sector US stocks on Pluang rose while 72 fell. Notable movers include Definium Therapeutics Inc. at USD 33.31 with a 9.72% increase and Immunovant Inc. at USD 31.09 with a 9.51% gain, while Illumina, Inc. dropped 9.50% to USD 205.01.
Arcutis Biotherapeutics awarded 58,500 restricted stock units and options for 17,000 shares to six new employees as an inducement to join the company. The grants, approved under Nasdaq Listing Rule 5635(c)(4), vest over four years with specific sched...
The music duo for KING + COUNTRY released the Drummer Boy (Original Motion Picture Soundtrack) to coincide with the nationwide launch of their Christmas film DRUMMER BOY. The soundtrack features original songs by Joel and Luke Smallbone, reimagined C...
HMG Strategy is holding its first Tennessee C-Level Technology Leadership Summit on November 13 at W Nashville, bringing together CIOs, CISOs, CTOs, and senior tech executives from across Tennessee and the Mid-South. The summit will focus on AI, cybe...
Researcher Derik Kauffman revealed that Apple's iOS keyboard uses a secret 'gray list' of over 100,000 words and phrases that it blocks from autocomplete and swipe-typing suggestions. The list includes vulgar, offensive, drug-related, and politically...
Calumet reported a strong Q3 performance, surpassing analyst expectations with an EPS of $2.91 versus the estimated $1.63, and EBITDA of $347 million compared to the expected $269 million. The Specialty Products segment benefited from limited global ...
